Evidence map›Paper›PMID 36745455›Full record

ArticleJAMA network open2023

Prevaccination Prevalence of Type-Specific Human Papillomavirus Infection by Grade of Cervical Cytology in Estonia.

Anneli Uusküla, Marek Oja, Sirli Tamm, Anna Tisler, Made Laanpere, Lee Padrik, Mari Nygard, Sulev Reisberg, Jaak Vilo, Raivo Kolde

Abstract read
In one paragraph

Article in JAMA network open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Anneli UuskülaDepartment of Family Medicine and Public Health, University of Tartu, Tartu, Estonia.
Marek OjaInstitute of Computer Science, University of Tartu, Tartu, Estonia.
Sirli TammInstitute of Computer Science, University of Tartu, Tartu, Estonia.
Anna TislerDepartment of Family Medicine and Public Health, University of Tartu, Tartu, Estonia.
Made LaanpereDepartment of Obstetrics and Gynaecology, Institute of Clinical Medicine, University of Tartu; Tartu University Hospital Women's Clinic, Tartu, Estonia.
Lee PadrikDepartment of Obstetrics and Gynaecology, Institute of Clinical Medicine, University of Tartu; Tartu University Hospital Women's Clinic, Tartu, Estonia.
Mari NygardDepartment of Research, Cancer Registry of Norway, Oslo, Norway.
Sulev ReisbergInstitute of Computer Science, University of Tartu, Tartu, Estonia.
Jaak ViloInstitute of Computer Science, University of Tartu, Tartu, Estonia.
Raivo KoldeInstitute of Computer Science, University of Tartu, Tartu, Estonia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: Large-scale data on type-specific human papillomavirus (HPV) prevalence and disease burden worldwide are needed to guide cervical cancer prevention efforts. Promoting the research and application of health care big data has become a key factor in modern medical research. Objective: To examine the prevaccination prevalence of high-risk HPV (hrHPV) and type distribution by cervical cytology grade in Estonia. Design, Setting, and Participants: This cross-sectional study used text mining and the linking of data from electronic health records and health care claims to examine type-specific hrHPV positivity in Estonia from 2012 to 2019. Participants were women aged at least 18 years. Statistical analysis was performed from September 2021 to August 2022. Main Outcomes and Measures: Type-specific hrHPV positivity rate by cervical cytological grade. Results: A total of 11 017 cases of cervical cytology complemented with data on hrHPV testing results between 2012 and 2019 from 66 451 women aged at least 18 years (mean [SD] age, 48.1 [21.0] years) were included. The most common hrHPV types were HPV16, 18, 31, 33, 51 and 52, which accounted for 73.8% of all hrHPV types detected. There was a marked decline in the positivity rate of hrHPV infection with increasing age, but the proportion did not vary significantly based on HPV type. Implementation of nonavalent prophylactic vaccination was estimated to reduce the number of women with high-grade cytology by 50.5% (95% CI, 47.4%-53.6%) and the number with low-grade cytology by 27.8% (95% CI, 26.3%-29.3%), giving an overall estimated reduction of 33.1% (95% CI, 31.7%-34.5%) in the number of women with precancerous cervical cytology findings. Conclusions and Relevance: In this cross-sectional study, text mining and natural language processing techniques allowed the detection of precursors to cervical cancer based on data stored by the nationwide health system. These findings contribute to the literature on type-specific HPV distribution by cervical cytology grade and document that α-9 phylogenetic group HPV types 16, 31, 33, 52 and α-7 phylogenetic group HPV 18 are the most frequently detected in normal-to-high-grade precancerous lesions in Estonia.

Indexed as

Papillomavirus InfectionsUterine Cervical NeoplasmsAdultCross-Sectional StudiesEstoniaFemaleHuman papillomavirus 16Human Papillomavirus VirusesHumansMiddle AgedPhylogenyPrevalence

Identifiers

PMID36745455
PMCPMC12527416

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.